Mitogen-activated protein kinases (MAPKs) are a group of serine/threonine kinases that are activated in response to a diverse array of extracellular stimuli, and mediate signal transduction from the cell surface to the nucleus. 1) MAPKs are composed of three major subgroups, namely, extracellularsignal-related kinase (ERK1/2), c-Jun N-terminal kinase (JNK), and p38. Intracellular signals arising from MAPK cascades invariably lead to the activations of a set of molecules that regulate cell growth, division, differentiation, and cellular responses to cytokines and stresses. Furthermore, recent studies have demonstrated that JNK activation plays a pivotal role in cancer cell death induced by cellular stresses and that this occurs via the regulations of transcription factors, such as, c-jun.
Many of the compounds used for cancer chemotherapy, such as, the Vinca alkaloids, paclitaxel, camptothecin, and etoposide were originally derived from plant sources, 3) and plants continue to be viewed as major sources for the development of new anti-cancer drugs.
Sesquiterpene lactones are colorless, bitter, relatively stable, lipophilic entities that are derived in vivo from trans farnesyl pyrophosphate via initial cyclization and subsequent oxidative modifications. Furthermore, sesquiterpene lactones exhibit a wide spectrum of biological activities, which include anti-tumor, antibiotic, anti-parasitic, and anti-inflammatory activities. 4) It has been reported that some sesquiterpenes induce the apoptosis of cancer cells. 5) Costunolide is a sesquiterpene lactone that was originally isolated from the stem bark of Magnolia sieboldii, and has been reported to have wide-ranging biological effects, which include anti-inflammatory, 6) anti-viral, 7) anti-fungal, 8) antimycobacterial, 9) pro-differentiation, and hypolipidemic 10) activities. Furthermore, costunolide has been reported to have a chemopreventive effect on intestinal carcinogenesis. 11) We previously demonstrated that costunolide induces the apoptosis of human leukemia cells by inducing reactive oxygen species (ROS)-mediated mitochondria permeability transition and consequent cytochrome c release. 12) Furthermore, Bcl-2 overexpression was found to completely block costunolide-induced apoptosis in U937 cells. 13) However, the mechanism whereby costunolide-induced ROS mediates apoptosis and its in vivo efficacy has not been demonstrated. Accordingly, in the present study, we examined the involvement of JNK activation in the apoptotic process induced by costunolide. Furthermore, we confirmed that costunolide can inhibit tumor growth and mortality in a Lewis lung carcinoma-bearing model.
MATERIALS AND METHODS

Materials
Costunolide used for this study was isolated from the stem bark of Magnolia sieboldii as previously described.
13) The identity of isolated compound was confirmed by HPLC and was found to be Ͼ98% pure. RPMI 1640 medium, fetal bovine serum (FBS), penicillin, and streptomycin were obtained from Life Technologies, Inc. (Grand Island, NY, U.S.A.). RNase, leupeptin, aprotinin, 4Ј,6-diamidino-2-phenylindole dihydrochloride (DAPI), N-acetyl-Lcysteine (NAC), Triton X-100, Nonidet P-40, and propidium iodide (PI) were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). Proteinase K was from Wako Pure Chemical Industries (Osaka, Japan). ERK1/2, phospho-ERK1/2 (p-ERK1/2), JNK, phospho-JNK (p-JNK), p38, phospho-p38 (p-p38), b-actin, and the peroxidase-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, U.S.A.).
Cell Culture U937 human promonocytic leukemia and 3LL Lewis mouse lung carcinoma cells were obtained from the Japanese Cancer Research Resources Bank (Tokyo, Japan) and the American Tissue Culture Collection (ATCC, Rocksville, Maryland, U.S.A.), respectively. Bcl-2-overexpressing U937 Bcl-2H cells 14) and c-jun dominant negative expressing U937 cells (U937 DN ) 14) were provided by Dr. K. Nakaya (School of Pharmaceutical Sciences, Showa University, Japan). Cells were cultured in RPMI 1640 (Life Technologies, Grand Island, NY, U.S.A.) supplemented with 10% heat-inactivated fetal bovine serum (FBS), penicillin (100 units/ml) and streptomycin sulfate (100 mg/ml) (Life Technologies Inc.) and incubated at 37°C in an atmosphere of 5% CO 2 in the presence or absence of costunolide.
Quantification of DNA Fragmentation and Apoptotic Cells DNA fragmentation was quantified as previously reported. 13) In brief, cells were lysed in a solution of 1 M Tris-HCl (pH 7.4) and 0.5 M ethylenediaminetetraacetic acid (EDTA) containing 0.5% (w/v) Triton X-100 for 20 min on ice. After centrifugation at 25000ϫg for 20 min, the lysate and supernatant were sonicated for 15 s and the level of DNA in each fraction was measured by a fluorometric method using DAPI. The amount of the fragmented DNA was calculated as the ratio of the amount of DNA in the supernatant to that in the lysate. Fluorescent staining of nuclei was carried out to determine apoptotic cells. After treatment, cells were washed with phosphate-buffered saline (PBS) and fixed in MeOH-HAc (3 : 1, v/v) for 10 min at 4°C. Cells were stained with Hoechst 33258 (5 mg/ml in PBS) for 5 min at room temperature and then examined in a fluorescent microscope at 356 nm (Olympus Corporation, Tokyo, Japan).
Propidium Iodide (PI) Staining and Flow Cytometry Analysis On the day of collection, the cells were harvested and washed twice with ice-cold PBS. The cells were fixed and permeabilized with 70% ice-cold ethanol at 4°C for 1 h. The cells were washed once with PBS and resuspended in a staining solution containing propidium iodide (50 ml/ml) and RNase A (250 mg/ml). The cell suspensions were incubated for 30 min at room temperature followed by fluorescence-activated cell sorting (FACS) cater-plus flow cytometry (Becton Dickinson Co., Heidelberg, Germany) using 10000 cells per each group.
Cell Fractionation and Western Blot Analysis Cells were collected by centrifugation at 200ϫg for 10 min at 4°C. The cells were then washed twice with ice-cold PBS, pH 7.2, and centrifuged at 200ϫg for 5 min. The cell pellet obtained was then resuspended in ice-cold cell extraction buffer (20 mM Hepes-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM ethylene glycol bis(2-aminoethyl ether)-N,N,NЈ,NЈ-tetra acetic acid (EGTA), 1 mM dithiothreitol, 100 mM phenylmethylsulfonyl fluoride (PMSF), and protease inhibitor cocktail) for 30 min on ice. The cells were then homogenized with a glass dounce and a B-type pestle (80 strokes), homogenates were spun at 15000ϫg for 15 min at 4°C, and the supernatant (cytosolic fraction) was removed whilst taking care to avoid the pellet. Approximately 30 mg of cytosolic protein extracts was separated using 12% SDSpolyacrylamide gels and transferred to nitrocellulose. The blots were incubated with ERK1/2, p-ERK1/2, JNK, p-JNK, p38, p-p38, and b-actin antibodies followed by enhanced chemiluminescence (ECL)-based detection (Amersham Pharmacia Biotech, Uppsala, Sweden).
In Vitro Kinases Assay JNK activity was quantified using in vitro kinase assay kit from Cell Signaling Technology (Danvers, MA, U.S.A.) according to the manufacturer's instructions. Briefly, proteins were isolated from cell lysate and concentrations determined. An equal amount of protein was incubated with c-Jun fusion protein beads overnight at 4°C. After several washes with 1ϫcell lysis buffer and kinase buffer, beads were resuspended in 20 ml of kinase buffer supplemented with 100 mM ATP and incubated 30 min at 30°C. The reaction was terminated with 10 ml of 3ϫsodium dodecyl sulfate (SDS) sample buffer (1ϫSDS buffer: 62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 50 mM DTT). Samples were boiled for 5 min and separated by 10% SDS-PAGE. Western blotting was performed as described above. The phosphorylated GST-c-Jun fusion protein was detected using anti-phosphorylated c-Jun antibody.
Animals and Tumors Male inbred CDF 1 mice weighing 20-25 g from Charles River (Japan) were used. CDF 1 mice were inoculated subcutaneously with 3LL Lewis lung carcinoma cells (5ϫ10 5 cells) and tumors were allowed to grow for one week (the size of tumor at this point was approximately 300 mm 3 ). The tumor-bearing mice were randomly divided into 4 groups consisted of 10 mice. Costunolide (7.5, 15, 30 mg/kg) was administrated every day intraperitoneally (i.p.) for a week. The control group was treated with vehicle mixture alone. Survival of mice was monitored every day. Tumor size was measured every 3 d using calipers and calculated using the ellipsoid formula as described previously. 15) Statistical Analysis Results are expressed as the meansϮS.D. of triplicate experiments. Statistical analysis was performed using Student's t-test, and p-values of less than 0.05 were considered statistically significant.
RESULTS
Costunolide Activated JNK in Human Leukemia Cells
To determine whether costunolide-induced apoptosis is mediated through MAPK pathways, we examined the phosphorylation of ERK1/2, JNK, and p38 by Western blotting. It was found that costunolide markedly increased JNK phosphorylation in U937 cells (with a peak at 60 min), whereas it only mildly increased ERK1/2 activation at 60 and 120 min and did not affect p38 activation (Fig. 1A) . Furthermore, similar patterns of MAPK activations after treatment with costunolide were observed in HL-60 human promyelocytic leukemia cells (data not shown).
In view of the fact that JNK is usually responsible for the phosphorylation of c-Jun in the stress-activated signal transduction pathway, we performed in vitro kinase assays to investigate the activity and potential role of JNK following costunolide treatment (10 mM). As shown in Fig 1B, JNK activity was low in untreated control U937 cells but increased dramatically after treatment for 30 and 60 min.
Costunolide-Induced Apoptosis Was Associated with JNK Activation To examine the effects of JNK activation on the apoptosis of U937 cells, cells were treated with costunolide and/or sorbitol (a JNK stimulator). Numbers of cells in the sub-G1 population, hypodiploid apoptotic cells, were measured by flow cytometry. It was found that co-treating U937 cells with costunolide (5 mM) and sorbitol (100 mM) had an additive effect on JNK activation ( Fig. 2A) . Furthermore, treatment with costunolide or sorbitol increased hypodiploidic cell numbers by 19% or 6%, respectively, compared to the untreated control. Moreover, costunolide plus sorbitol treatment increases the sub-G1 population by 45% (Fig. 2B) . Two stable cell lines, U937 DN1 and U937 DN2 , that constitutively expressed a dominant-negative mutation of cjun, and which showed significant inhibition of the JNK signaling pathway, were used to test the involvement of the JNK-c-jun pathway in costunolide-induced apoptosis. Subsequent experiments on these cells indicated that the expression of dominant negative c-jun significantly inhibited the costunolide-induced DNA fragmentation (Fig. 3A) and the development of apoptotic morphology (Fig. 3B) . In addition, the JNK inhibitor SP600125 substantially attenuated the costunolide-induced apoptosis while the p38 inhibitor SB203580 or the ERK1/2 specific inhibitor PD98059 did not affect it (Fig. 3C) . These results suggest that costunolide activates the JNK pathway, and that this plays an important role in the pro-apoptotic activity of costunolide.
Costunolide-Induced JNK Activation Was Inhibited by NAC but not by Bcl-2 Overexpression We previously demonstrated that both treatment with the antioxidant NAC and Bcl-2 overexpression completely reverse costunolide-induced apoptosis in U937 cells. 13) In this study, we investigated whether JNK activation by costunolide acts downstream or upstream of ROS and Bcl-2. Cells were treated with costunolide with/without NAC (5 mM), and the phosphorylation of JNK was investigated by Western blotting. Costunolide-stimulated JNK activation was found to be completely abolished by NAC pretreatment (Fig. 4A) . In contrast, Bcl-2 overexpression failed to reverse the JNK activation by costunolide (Fig. 4B) . Previously, we have demonstrated that costunolide suppressed Bcl-2 expression in U927 cells. 13) In this study, we tested whether JNK inhibitor can recover the costunolide-suppressed Bcl-2 expression. As shown in Fig. 5 , treatment with costunolide significantly decreased the Bcl-2 expression and the decrease was substantially recovered by pretreatment with SP600125 (10 mM). These data indicate that costunolide-induced JNK activation acts downstream of reactive oxygen species (ROS) but upstream of Bcl-2.
Costunolide Inhibited the Growth of Tumors Implanted in Mice Costunolide induced apoptosis in 3LL Lewis Lung carcinoma and JNK inhibitor SP600125 attenuates the costunolide-induced apoptosis in vitro (Supple. Fig.  1 ). Due to our promising in vitro results, the anti-tumor effect of costunolide was examined in vivo efficacy in 3LL Lewis lung carcinoma-bearing mice. Costunolide administered at 7.5, 15, or 30 mg/kg daily via the i.p. for 7 d from day 7 of implantation was found to inhibit significantly the growth of Lewis lung carcinoma as compared with vehicle controls in a dose-dependent manner (Fig. 6A) . In particular, the administrations of costunolide at 7.5 or 15 mg/kg produced 67% and 50% survivals at day 45, respectively, whereas no untreated control or 30 mg/kg treated mouse survived (Fig. 6B) . Furthermore, there was no weight loss in non-tumor-bearing mice treated with costunolide (7.5 mg/kg) (Supple. Fig. 2 ).
DISCUSSION
Apoptosis is a selective process of physiological cell deletion that plays an important role in the balance between cellular replication and death. Moreover, it has been suggested that some cancer chemotherapeutics and chemopreventives exert their effects by triggering either apoptotic cell death or cell cycle transition, and accordingly, the induction of tumor cell apoptosis is used to predict tumor treatment response. 16, 17) On the other hand, it has also been found that several tumor promoters inhibit apoptosis. 17) Due to their anti-cancer properties, several sesquiterpene lactones, such as, helenalin, costunolide, parthenolide, and sclareolide have attracted considerable attention, and numerous studies have characterized their molecular mechanisms and identified potential chemotherapeutic applications. 18, 19) Furthermore, an increasing body of evidence suggests that MAPKs as well as nuclear transcription factor-kappaB (NFkB) are involved in the anti cancer activities of sesquiterpene lactones. 4) For example, helenalin and parthenolide were found to enhance ATRA (all-trans retinoic acid)-induced HL-60 cell differentiation through the ERK1/2 pathway, and JNK was found to be involved in the differentiation induced by parthenolide. 19) Furthermore, pretreatment with parthenolide sustained TNF-a-induced JNK activation and promoted apoptosis. Pretreatment with a JNK specific inhibitor and the overexpression of dominant-negative JNK reversed parthenolide-apoptosis in human cancer cells. 18) In a previous study on the anti-inflammatory, the effect of costunolide on MAPK signaling was investigated in LPS-stimulated RAW 264.7 cells. 20) It was found that costunolide inhibited the phosphorylations of both JNK and p38 MAPK, and that pretreatment with specific JNK or p38 inhibitors attenuated LPS-increased IL-1b expression. 20) These findings suggest that suppression of the MAPK signaling pathway may contribute to the antiinflammatory properties of costunolide.
Regarding the anti-cancer effects of costunolide, a recent To confirm the biological effect of DN-c-jun in U937 cells stably transfected with DN-c-jun, cells transfected with DN-c-jun or empty vector (controls) were treated with costunolide for 6 h, and apoptosis was followed using DNA fragmentation (A) and fluorescent staining of nuclei to (B). The data presented are the meansϮS.D. of three independent experiments. # pϽ0.01 vs. 0 h (in U937 and U937v cells), * pϽ0.01 vs. U937v 6 h treated cells; significance of difference between treated groups was determined using the Student's t-test. (C) To confirm the biological effect of ERK1/2, p38, and JNK on costunolide-induced apoptosis in U937, the cells were treated with costunolide for 6 h in the present or absent of PB98059 (ERK1/2 inhibitor, 10 mM), SB203580 (p38 inhibitor, 10 mM), or SP600125 (JNK inhibitor, 10 mM), and apoptosis was followed using fluorescent staining of nuclei. The data presented are the meansϮS.D. of three independent experiments. # pϽ0.01 vs. w/o costunolide, * pϽ0.01 vs. w costunolide; significance of difference between treated groups was determined using the Student's t-test. study demonstrated that costunolide enhances ATRA-induced HL-60 cell differentiation into a granulocytic lineage. Furthermore, signaling kinases, including protein kinase C (PKC), phosphoinositide 3-kinase (PI3K), ERK1/2, and JNK, were found to be involved in costunolide-enhanced differentiation. 19) In the present study, we investigated whether MAPKs are associated with costunolide-induced apoptosis in human leukemia cells. It was found that costunolide dramatically increased JNK activation and that this activation mediated costunolide-induced apoptosis (Figs. 2, 3) . The observation that ERK1/2 was slightly activated by costunolide was interesting, but pretreatment with a specific ERK1/2 inhibitor showed no significant effect on costunolide-induced apoptosis (data not shown). Summarizing, the above findings suggest that JNK activation, but not ERK1/2 activation, plays a key role in the apoptosis induced by costunolide, and that costunolide-induced differentiation 19) and apoptosis involve different signaling pathways in human leukemia cells.
Previously, we demonstrated that ROS-mediated mitochondrial permeability transition plays a pivotal role in costunolide-induced apoptosis, 12) and that the overexpression of mitochondrial anti-apoptotic Bcl-2 protein can prevent apoptosis by costunolide. 13 ) Furthermore, it is well known that JNK stimulates apoptosis by regulating Bcl-2 family members. 21) For example, active JNK inhibits the anti-apoptotic function of Bcl-2 via Bcl-2 phosphorylation, whereas JNK induces translocation of Bax to mitochondria 22, 23) and the phosphorylations of Bim and Bmf, 24) which increase apoptosis. In addition, accumulating evidence indicates that ROSor RNS-induced JNK signaling pathway mediates cell death. 25) In this study, we found that NAC pre-treatment, but not Bcl-2 overexpression, abolished costunolide-stimulated JNK activation. These findings suggest that ROS is required for JNK activation and that Bcl-2 is a downstream target of ROS-mediated JNK activation.
Despite the promising results produced by in vitro studies on sesquiterpene lactones, few in vivo studies have been undertaken to investigate their anti-cancer effects. In the present study, we performed an in vivo study using 3LL Lewis lung carcinoma-bearing model in addition to the in vitro mechanistic study. Costunolide was found to inhibit tumor growth successfully in a dose-dependent manner (7.5, 15, 30 mg/kg). However, it is noteworthy that when administered at 30 mg/kg costunolide failed to extend survival and decreased the body weight as compared to the vehicle treated controls, which suggests that at high doses costunolide is toxic. These data suggest that clinical application of costunolide will require structure-activity relation (SAR) studies to find costunolide analogs with decreased toxicity and improved therapeutic index or careful dosage adjustment and patient monitoring. The present study is the first to demonstrate the inhibitory effect of costunolide on tumor growth in a 3LL Lewis lung carcinoma-bearing model.
Summarizing, this study demonstrates that JNK, activated by costunolide, acts downstream of ROS but upstream of Bcl-2, and appears to contribute to costunolide-induced apoptosis in human leukemia cells. Furthermore, it shows that at optimal concentrations, costunolide suppresses tumor growth and increases survival rate in 3LL Lewis lung carcinoma-bearing model. 
